Drug
Decitabine clinical trials
Also written Dacogen and DAC.
- studies test it
- 314
- open now
- 62
- in phase 3
- 33
- first study started
- 1995
Keep track of what changes. Save the Decitabine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
313 studies that test it; most in 2017 (27); 1 more planned to start later
| Year | Studies |
|---|---|
| 1995 | 1 |
| 1997 | 1 |
| 1998 | 1 |
| 1999 | 1 |
| 2001 | 2 |
| 2002 | 6 |
| 2003 | 4 |
| 2004 | 6 |
| 2005 | 6 |
| 2006 | 8 |
| 2007 | 7 |
| 2008 | 13 |
| 2009 | 12 |
| 2010 | 10 |
| 2011 | 8 |
| 2012 | 13 |
| 2013 | 18 |
| 2014 | 20 |
| 2015 | 10 |
| 2016 | 15 |
| 2017 | 27 |
| 2018 | 19 |
| 2019 | 15 |
| 2020 | 15 |
| 2021 | 5 |
| 2022 | 14 |
| 2023 | 13 |
| 2024 | 10 |
| 2025 | 15 |
| 2026 | 18 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 4
- Phase 1
- 147
- Phase 2
- 186
- Phase 3
- 33
- Phase 4
- 8
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
- Leukemia
- 14
Who runs them
Industry 44 · Other 270
M.D. Anderson Cancer Center (32) · National Cancer Institute (NCI) (28) · Chinese PLA General Hospital (12) · Ruijin Hospital (11) · The First Affiliated Hospital of Soochow University (9) · Eisai Inc. (9) · Washington University School of Medicine (8) · Roswell Park Cancer Institute (7)
Often tested with
Tested in the same studies.
Venetoclax (35) · Cytarabine (33) · Azacitidine (21) · Cedazuridine (11) · Vorinostat (9) · Tetrahydrouridine (7) · Tucidinostat (7) · Filgrastim (6)
Studies
Open first, then newest update. How each study uses Decitabine is read from its arms, and is right about nine times in ten.
Testing it · 314
- A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid LeukemiaRecruitingPhase 1National Cancer Institute (NCI)NCT07012044Written as Decitabine
- Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AMLNot yet recruitingPhase 1Northside Hospital, Inc.NCT07511062Written as Decitabine
- Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage MesotheliomaRecruitingPhase 2National Cancer Institute (NCI)NCT05960773Written as Decitabine/cedazuridine
- A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.RecruitingPhase 1/2University of ChicagoNCT07389239Written as Decitabine
- Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AMLNot yet recruitingPhase 2Rutgers, The State University of New JerseyNCT07867626Written as decitabine/cedazuridine
- Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell TransplantRecruitingPhase 1/2Benjamin TomlinsonNCT06129734Written as Decitabine
- Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease MarkerRecruitingPhase 2The Methodist Hospital Research InstituteNCT07060001Written as Decitabine 20 mg/m²/day for 5 days
- Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor OlutasidenibRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06445959Written as Decitabine
- A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid LeukemiaRecruitingPhase 1M.D. Anderson Cancer CenterNCT06401603Written as Decitabine
- Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT03661307Written as Decitabine
- Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML PatientsRecruitingPhase 2PETHEMA FoundationNCT07507760Written as Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
- A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)RecruitingPhase 2M.D. Anderson Cancer CenterNCT06561074Written as Decitabine
- Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsRecruitingPhase 2University of WashingtonNCT04282187Written as Decitabine
- Hydrochloroquinine & Decitabine With Venetoclax in AMLNot yet recruitingPhase 1Rutgers, The State University of New JerseyNCT07814339Written as Oral Decitabine/cedazuridine
- Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid MalignanciesRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06383572Written as Decitabine
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingPhase 2/3Beat AML, LLCNCT03013998Written as Decitabine (BAML-16-001-S5)
- A Study of VABu Conditioning Regimen in Allo-HSCT for AML PatientsNot yet recruitingNot applicableThe First Affiliated Hospital of Soochow UniversityNCT07762508Written as Decitabine 20 mg/m²/day for 5 days
- Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative NeoplasmsRecruitingPhase 2University of WashingtonNCT07148947Written as Decitabine
- Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)RecruitingPhase 2M.D. Anderson Cancer CenterNCT01515527Written as Decitabine
- Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck CancerRecruitingPhase 1Mayo ClinicNCT06997094Written as Decitabine
See all 314 studies that test Decitabine →
Given in every arm · 63 — Decitabine is usual care beside what is tested
- Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingPhase 2M.D. Anderson Cancer CenterNCT00801489Written as Decitabine
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic LeukemiaRecruitingPhase 2Mayo ClinicNCT03418038Written as Decitabine
- A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid MalignanciesRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06930651Written as Decitabine
- High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)RecruitingPhase 1Kittika PoonsombudlertNCT07177079Written as Decitabine
- Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AMLRecruitingPhase 1David AviganNCT07374029Written as Decitabine
- Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid MalignanciesRecruitingPhase 1University of Alabama at BirminghamNCT07044544Written as Decitabine
- Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRDRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06511882Written as Decitabine
- Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)Enrolling by invitationEarly Phase 1BGI, ChinaNCT06499025Written as Decitabine Injection
- Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse PreventionRecruitingPhase 2Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT06686108Written as Decitabine (DAC)
- Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT MutationRecruitingPhase 2Children's Hospital of Soochow UniversityNCT06316960Written as Decitabine Injection
- Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDSRecruitingPhase 2Anhui Provincial HospitalNCT06109064Written as Decetabine
- Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AMLRecruitingPhase 2Anhui Provincial HospitalNCT06105658Written as Decetabine
- Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) PatientsNot yet recruitingNot applicableThe First Affiliated Hospital of Soochow UniversityNCT05805072Written as Decitabine
- Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled TrialRecruitingPhase 3Huihan WangNCT05382390Written as Decitabine
- Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen ReceptorRecruitingPhase 1/2Chinese PLA General HospitalNCT04337606Written as Decitabine
- Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCTRecruitingPhase 2/3Peking University People's HospitalNCT03793517Written as Decitabine
- Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or RefractorySuspendedPhase 1City of Hope Medical CenterNCT03969446Written as Decitabine
- A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)TerminatedPhase 1Taiho Oncology, Inc.NCT05403450Written as Decitabine + Cedazuridine
- Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.Active, not recruitingPhase 2Novartis PharmaceuticalsNCT05201066Written as decitabine
- Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AMLActive, not recruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT06429098Written as decitabine
Showing 20 of 63.
As the comparator · 7 — what is tested is compared with Decitabine
- HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AMLRecruitingPhase 3Sunshine Lake Pharma Co., Ltd.NCT05586074Written as Decitabine
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th SalvageTerminatedPhase 3Delta-Fly Pharma, Inc.NCT03926624Written as Decitabine
- Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2Active, not recruitingPhase 3Sellas Life Sciences GroupNCT04229979Written as Decitabine
- Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART TrialSuspendedPhase 2Johns Hopkins UniversityNCT04482621Written as Decitabine
- A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid LeukemiaTerminatedPhase 1PfizerNCT02954653Written as Decitabine
- Trial of Decitabine in Patients With Acute Myeloid LeukemiaCompletedPhase 3Eisai Inc.NCT00260832Written as Dacogen (decitabine) only
- Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDSStatus unknownPhase 2/3Xiao LiNCT01417767Written as 5-aza-deoxycytidine
Codes
What other systems call Decitabine · ClinicalTrials.gg INT006664
- MeSH (NLM) D000077209DecitabineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 776B62CQ27DECITABINEConfirmed FDA, NLM, Wikidata
- RxNorm 15657Confirmed FDA, Wikidata
- Wikidata Q1181878decitabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C981DecitabineOne source FDA
- DrugBank DB01262One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077209 | Decitabine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 776B62CQ27 | DECITABINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 15657 | — | Confirmed FDA, Wikidata |
| Wikidata | Q1181878 | decitabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C981 | Decitabine | One source FDA |
| DrugBank | DB01262 | — | One source Wikidata |
Also registered as decitabine mesylate (UNII 6U3LPL9PRN).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.